Advanced Conjugate Delivery Systems for Oligonucleotides
Oligonucleotide therapeutics represent a transformative treatment modality with demonstrated potential across metabolic disorders, CNS diseases, muscular dystrophies, and a broad spectrum of genetically driven conditions. However, their clinical advancement is significantly hindered by the lack of efficient and specific delivery strategies. Recent progress in conjugate-based delivery systems offers potential solutions for improving the safety and targeted delivery of oligonucleotides to various tissues and organs.
At TIDES Asia 2026, WuXi Biology presented a poster describing the establishment of an integrated service platform to accelerate the discovery of oligonucleotide drugs. The authors highlight case studies with data showing the uptake/efficacy of lipid-conjugated siRNAs, as well as the evaluation of mRNA display–based peptide discovery and the uptake/efficacy of peptide-oligonucleotide conjugates.

Poster_TIDES Asia 2026_Accelerating Oligonucleotide Therapeutics via Advanced Conjugate Delivery Systems
Related Content
Cognitive dysfunction affects over 50 million individuals worldwide, with Alzheimer’s disease (AD) representing two-thirds of cases. Due to the complexity...
VIEW RESOURCEAntibody-targeted therapies—including antibody-drug conjugates (ADCs), antibody-oligonucleotide conjugates (AOCs), and degrader-antibody conjugates (DACs)—are reshaping precision medicine by enabling highly selective delivery...
VIEW RESOURCE
